At Fluxion, we’re passionate about delivering cell-based and cell-free solutions that facilitate the transformation of research discoveries into new ways to diagnose and treat patients. By characterizing molecular and cellular mechanisms of disease, Fluxion’s platforms help bridge the translational medicine gap, enabling rapid advances in disease research, drug discovery, and the development of diagnostic tests.
Andrew Cook, Senior Study Director, Eurofins Discovery Services.
Nicotinic acetylcholine receptors are a subset of cholinergic receptors that respond to acetylcholine. Target disorders that may be linked to nicotinic ion channels as a potential for drug discovery include muscle dystrophies, myasthenia gravis and myogenic disorders. With integrated solution control and rapid fluid exchange, the IonFlux system is ideally suited to ligand-gated ion channel research. We developed and validated high throughput automated patch clamp assays for nAChR ion channels to profile new chemical entities for drug discovery. These assays are capable of screening much larger libraries than previously feasible by conventional whole cell patch clamp and provide more functional information than fluorometric methods.